Misonix, Inc. To Report Financial Results Of First Quarter Fiscal 2013 On
Thursday, November 1, 2012
Conference call to be conducted at 4:30 pm ET
FARMINGDALE, N.Y., Oct. 25, 2012 /PRNewswire via COMTEX/ -- Misonix, Inc. (MSON),
a surgical device company that designs, manufactures and markets innovative
therapeutic ultrasonic products worldwide for wound debridement, spinal surgery,
cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical
applications, announced today that it will report financial results for the first
quarter of fiscal year 2013 ended September 30, 2012 on Thursday, November 1,
2012. The Company has scheduled a conference call that same day, Thursday,
November 1, 2012, at 4:30 pm ET to review the results.
Interested parties can access the conference call by dialing (877) 317-6789 or
(412) 317-6789 or can listen via a live Internet webcast, which is available in
the Investor Relations section of the Company's website at
misonix.com.
A teleconference replay of the call will be available for three days at (877)
344-7529 or (412) 317-0088, confirmation # 10020438. A webcast replay will be
available in the Investor Relations section of the Company's website at
misonix.com for 30 days.
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic
medical devices. Misonix's therapeutic ultrasonic platform is the basis for
several innovative medical technologies. Addressing a combined market estimated
to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical
devices are used for wound debridement, cosmetic surgery, neurosurgery,
laparoscopic surgery, and other surgical and medical applications. Additional
information is available on the Company's Web site at misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation Reform Act of
1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that could cause
actual results to differ materially from the statements made. These factors
include general economic conditions, delays and risks associated with the
performance of contracts, risks associated with international sales and currency
fluctuations, uncertainties as a result of research and development, acceptable
results from clinical studies, including publication of results and
patient/procedure data with varying levels of statistical relevancy, risks
involved in introducing and marketing new products, potential acquisitions,
consumer and industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory risks
including approval of pending and/or contemplated 510(k) filings, the ability to
achieve and maintain profitability in the Company's business lines, and other
factors discussed in the Company's Annual Report on Form 10-K, subsequent
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking relationships.
Company Contact:Investor Contacts:
Richard ZarembaRobert Blum, Joe Dorame, Joe Diaz
Misonix, Inc.Lytham Partners, LLC
631-694-9555602-889-9700
invest@misonix.com mson@lythampartners.com
misonix.comhttp://www.lythampartners.com
SOURCE Misonix, Inc. |
